Senseonics - SENS STOCK NEWS

Senseonics Holdings, Inc. (SENS) announced the enrollment of its first pediatric participant in the ENHANCE clinical trial for the Eversense® 365-day continuous glucose monitoring (CGM) system. This pivotal trial, directed by Dr. Timothy Bailey at AMCR Institute, aims to evaluate the system's accuracy and safety over one year, with a focus on extending its benefits to young diabetes patients aged 14 to 18. With previous data from over 165 adult subjects and an expected completion of the last patient visit in Q3 2023, successful trial outcomes could bolster the company's position in the diabetes management market. Senseonics emphasizes the device's unique benefits, allowing pediatric users to remove transmitters during activities, enhancing their quality of life while managing diabetes.

Senseonics Holdings, Inc. (NYSE American: SENS) has granted equity awards to 13 new non-executive employees under its 2019 Inducement Plan. On April 4, 2023, the Compensation Committee approved non-qualified stock options for 200,000 shares and restricted stock units for 250,000 shares, with an exercise price of $0.5951 per share. The options and units will vest over time, contingent on continuous employment. Senseonics focuses on developing innovative long-term implantable glucose monitoring systems aimed at improving diabetes management.

Senseonics Holdings, Inc. (SENS) reported financial results for Q4 and full year 2022, revealing a total revenue of $16.4 million for 2022, up from $13.7 million in 2021. Notably, Q4 2022 revenue reached $5.6 million, marking a rise from $4.0 million in Q4 2021. Gross profit for the full year was $2.7 million, a significant improvement from a gross loss of $0.8 million. The company achieved a net income of $142.1 million in 2022, compared to a net loss of $302.5 million the previous year. Senseonics also anticipates revenue growth for 2023, projecting a range of $20 million to $24 million, indicating an increase of 22% to 46% compared to 2022.

Senseonics (AMEX:SENS) will release its fourth quarter and full year 2022 financial results after market close on March 15, 2023. A joint virtual event with PHC Holdings and Ascensia Diabetes Care will take place on the same day at 6:30 pm ET, featuring presentations from executives including Tim Goodnow and Rick Sullivan. They will discuss the Eversense technology portfolio, commercial partnerships, and provide financial guidance. The webcast will be accessible on Senseonics' website under “Investor Relations” for future reference.

Senseonics Holdings, Inc. (NYSE American: SENS) announced it granted equity to 10 new non-executive employees under its 2019 Inducement Plan. On January 5, 2023, the Compensation Committee awarded non-qualified stock options totaling 115,000 shares at an exercise price of $1.02, reflecting the closing share price on the grant date. The options will vest 25% on the first anniversary of employment and monthly thereafter over three years, contingent on continued service. Senseonics specializes in long-term implantable continuous glucose monitoring systems for diabetes management.